IFP Advisors’s Abeona Therapeutics ABEO Stock Holding History

IFP Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-400	Closed	-$2K	–	3356
2022 Q4	$2K	Buy	+400	New	+$1.5K	﹤0.01%	4099
2022 Q3	–	Sell	-400	Closed	-$1.65K	–	1486
2022 Q2	$175K	Hold	400	–	–	0.01%	1343
2022 Q1	$175K	Buy	+400	New	+$2.75K	0.01%	1343
2019 Q1	$74K	Hold	400	–	–	0.01%	804
2018 Q4	$70K	Hold	400	–	–	﹤0.01%	1397
2018 Q3	$128K	Hold	400	–	–	0.01%	1330
2018 Q2	$160K	Sell	400 -80	-17%	-$35K	0.01%	1196
2018 Q1	$190K	Hold	480	–	–	0.01%	1013
2017 Q4	$190K	Sell	480 -520	-52%	-$215K	0.01%	1018
2017 Q3	$426K	Hold	1,000	–	–	0.02%	752
2017 Q2	$160K	Hold	1,000	–	–	0.01%	1255
2017 Q1	$125K	Hold	1,000	–	–	0.01%	1369
2016 Q4	$121K	Hold	1,000	–	–	0.01%	1329
2016 Q3	$150K	Hold	1,000	–	–	0.01%	1139
2016 Q2	$59K	Buy	1,000 +600	+150%	+$41K	﹤0.01%	1666
2016 Q1	$74K	Sell	400 -600	-60%	-$39.7K	0.01%	804
2015 Q4	$84K	Buy	+1,000	New	+$100K	0.01%	1274

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IFP Advisors's ABEO Position: Q1 2023 in Review

IFP Advisors sold out of Abeona Therapeutics (ABEO) in Q1 2023, closing a stake of 400 shares — an estimated $2K sold.

IFP Advisors first reported a position in ABEO in Q4 2015 and held it in 17 quarters. The position peaked at $426K in Q3 2017. 33 funds tracked by Wall St. Rank hold ABEO as of Q1 2023.

IFP Advisors reported no remaining Abeona Therapeutics position as of Q1 2023 after selling out during the quarter.
IFP Advisors sold 400 Abeona Therapeutics shares in Q1 2023, an estimated $2K.
IFP Advisors first reported a position in Abeona Therapeutics in Q4 2015 and held it in 17 quarters.
IFP Advisors's Abeona Therapeutics position peaked at $426K in Q3 2017.
33 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2023.

Based on IFP Advisors's 13F filing for Q1 2023, filed 18 Apr 2023.